Trader consensus prices "No" at an 87.5% implied probability for a CDC Level 4 Travel Health Notice—"Avoid All Travel," reserved for extreme life-threatening disease risks—by December 31, 2026, due to the complete absence of such alerts in 2026 despite vigilant surveillance. As of the CDC's May 7 update, no Level 4 or even Level 3 notices exist; the highest are Level 2 for meningococcal disease in the Democratic Republic of the Congo (March 24), yellow fever in Venezuela (March 16), and chikungunya outbreaks in Mayotte and elsewhere. These reflect localized transmission without the uncontrolled escalation historically triggering Level 4, like early COVID-19 waves. The 2025-2026 influenza season reports 155 pediatric deaths but no international travel restrictions. Ongoing CDC and WHO monitoring could shift odds if novel pathogens surge, with weekly FluView updates providing key data.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedCDC issues Level 4 warning by December 31?
CDC issues Level 4 warning by December 31?
$71,303 Vol.
$71,303 Vol.
$71,303 Vol.
$71,303 Vol.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Market Opened: Jan 19, 2026, 3:15 PM ET
Resolver
0x65070BE91...A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Trader consensus prices "No" at an 87.5% implied probability for a CDC Level 4 Travel Health Notice—"Avoid All Travel," reserved for extreme life-threatening disease risks—by December 31, 2026, due to the complete absence of such alerts in 2026 despite vigilant surveillance. As of the CDC's May 7 update, no Level 4 or even Level 3 notices exist; the highest are Level 2 for meningococcal disease in the Democratic Republic of the Congo (March 24), yellow fever in Venezuela (March 16), and chikungunya outbreaks in Mayotte and elsewhere. These reflect localized transmission without the uncontrolled escalation historically triggering Level 4, like early COVID-19 waves. The 2025-2026 influenza season reports 155 pediatric deaths but no international travel restrictions. Ongoing CDC and WHO monitoring could shift odds if novel pathogens surge, with weekly FluView updates providing key data.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions